<div id="readability-page-1"><p>BNP Paribas Financial Markets raised its stake in  Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) by 17.7% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor  owned 665,795 shares of the company's stock after buying an additional 100,198 shares during the period. BNP Paribas Financial Markets owned 0.74% of Travere Therapeutics worth $25,440,000 at the end of the most recent quarter.</p><div><p><span></span><span>Get <strong>Travere Therapeutics</strong> alerts:</span></p></div><ul><li>3 Under-the-Radar Healthcare Companies</li></ul><p>Other hedge funds have also recently added to or reduced their stakes in the company. Raymond James Financial Inc. acquired a new position in shares of  Travere Therapeutics during the second quarter worth $33,000.  Torren Management LLC acquired a new position in shares of  Travere Therapeutics during the fourth quarter worth $38,000.  Comerica Bank lifted its holdings in shares of  Travere Therapeutics by 77.5% during the fourth quarter. Comerica Bank now owns 1,127 shares of the company's stock worth $43,000 after purchasing an additional 492 shares during the period.  Garner Asset Management Corp acquired a new position in shares of  Travere Therapeutics during the fourth quarter worth $69,000.  Finally, Headlands Technologies LLC acquired a new position in shares of  Travere Therapeutics during the second quarter worth $73,000. </p><h2>Insider Transactions at Travere Therapeutics</h2><p>In other news, CAO Sandra Calvin sold 21,977 shares of the firm's stock in a transaction dated Tuesday, April 14th. The shares were sold at an average price of $41.07, for a total value of $902,595.39. Following the completion of the sale, the chief accounting officer directly owned 42,353 shares of the company's stock, valued at approximately $1,739,437.71. This trade represents a 34.16% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Roy D. Baynes sold 32,750 shares of the business's stock in a transaction dated Tuesday, April 14th. The stock was sold at an average price of $41.29, for a total transaction of $1,352,247.50. Following the sale, the director directly owned 37,500 shares in the company, valued at $1,548,375. The trade was a 46.62% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 400,015 shares of company stock worth $15,895,428. Company insiders own  4.44% of the company's stock. </p><h2>Wall Street Analysts Forecast Growth</h2><ul><li>Travere Therapeutics Still On The Rise After Encouraging Data </li></ul><p>TVTX has been the topic of several recent analyst reports. HC Wainwright boosted their target price on shares of Travere Therapeutics from $57.00 to $67.00 and gave the company a &#34;buy&#34; rating in a report on Tuesday. Guggenheim boosted their target price on shares of Travere Therapeutics from $54.00 to $56.00 and gave the company a &#34;buy&#34; rating in a report on Friday, April 24th. Wedbush  restated an &#34;outperform&#34; rating and issued a $55.00 target price on shares of Travere Therapeutics in a report on Wednesday. Wall Street Zen lowered shares of Travere Therapeutics from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a report on Saturday, May 9th. Finally, Citigroup boosted their target price on shares of Travere Therapeutics from $59.00 to $62.00 and gave the company a &#34;buy&#34; rating in a report on Wednesday. Ten analysts have rated the stock with a Buy rating, two have issued  a Hold rating and one  has assigned  a Sell rating to the company. According to data from MarketBeat.com, Travere Therapeutics presently has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $48.92.</p><p><b>View Our Latest Stock Report on Travere Therapeutics</b></p><h2>Travere Therapeutics Trading Up 2.2%</h2><p>Shares of TVTX stock opened at $46.18 on Friday. Travere Therapeutics, Inc. has a 52-week low of $13.88 and a 52-week high of $48.61. The company has a debt-to-equity ratio of 3.16, a quick ratio of 3.08 and a current ratio of 3.13. The company has a 50-day simple moving average of $39.35 and a two-hundred day simple moving average of $34.71. The company has a market capitalization of $4.29 billion, a price-to-earnings ratio of -200.77 and a beta of 1.13. </p><p>Travere Therapeutics (NASDAQ:TVTX - Get Free Report) last released its earnings results on Monday, May 4th. The company reported $0.05 earnings per share for the quarter, beating analysts' consensus estimates of ($0.24) by $0.29. Travere Therapeutics had a negative net margin of 4.00% and a negative return on equity of 26.16%. The firm had revenue of $127.20 million during the quarter, compared to the consensus estimate of $136.23 million. During the same period in the prior year, the firm earned ($0.47) EPS. The company's revenue was up 55.6% compared to the same quarter last year.  Research analysts anticipate that  Travere Therapeutics, Inc. will post -0.26 EPS for the current fiscal year. </p><h2>Travere Therapeutics Profile</h2> (Free Report)<p>Travere Therapeutics, Inc <span>NASDAQ: TVTX<span></span></span> is a biopharmaceutical company headquartered in San Diego, California, dedicated to the development and commercialization of therapies for rare kidney and genetic disorders. The company's mission is to address unmet needs in conditions with limited treatment options by focusing on diseases that affect small patient populations. Travere combines research, development and commercial capabilities to bring innovative medicines to market.  </p><p>The company's lead product is sparsentan, a dual endothelin angiotensin receptor antagonist that has received accelerated approval from the U.S.</p><h2>See Also</h2><ul><li>Five stocks we like better than Travere Therapeutics</li><li>The Great AI Server Rotation Puts Hewlett Packard Enterprise and Super Micro Computer in Focus</li><li>Generac’s AI Power Pivot Raises a Bigger Question About Data Center Demand</li><li>Medtronic Bottoms, Healthy Rebound Ahead</li><li>GitLab’s Price Recovery Gains Traction—Time to Get On Board?</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VFZUWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VFZUWA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Travere Therapeutics Right Now?</h2><p>Before you consider Travere Therapeutics, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Travere Therapeutics wasn't on the list.</p><p>While Travere Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

TVTX

<p>BNP Paribas Financial Markets increased its stake in Travere Therapeutics by 17.7% to $25.44 million in Q4. Other institutions like Comerica Bank also raised holdings, while insiders sold shares under Rule 10b5-1 plans. Analysts generally maintain a 'Moderate Buy' consensus with an average target price of $48.92, despite recent earnings beating estimates.</p>

Market Beat

Travere Therapeutics

BNP Paribas

Raymond James Financial

Comerica

Citigroup

RAYMOND JAMES FINANCIAL INC 6.375%DEP SHS REP 1/40TH FXD FLTG SER B

COMERICA INC 6.875 % DEP PFD SER B

CITIGROUP INC 6.250 NON CUM SER II PFD WI

BNP Paribas Financial Markets Has $25.44 Million Stock Position in Travere Therapeutics, Inc. $TVTX